- Home
- ACON vs KZIA Comparison
ACON vs KZIA Comparison
Compare ACON & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- KZIA
- Stock Information
- Founded
- ACON 2008
- KZIA 1994
- Country
- ACON United States
- KZIA Australia
- Employees
- ACON N/A
- KZIA N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- KZIA Health Care
- Exchange
- ACON Nasdaq
- KZIA Nasdaq
- Market Cap
- ACON 4.8M
- KZIA 5.1M
- IPO Year
- ACON 2022
- KZIA 1999
- Fundamental
- Price
- ACON $6.87
- KZIA $5.65
- Analyst Decision
- ACON Buy
- KZIA Strong Buy
- Analyst Count
- ACON 2
- KZIA 2
- Target Price
- ACON $481.00
- KZIA $57.50
- AVG Volume (30 Days)
- ACON 17.8K
- KZIA 24.0K
- Earning Date
- ACON 05-15-2025
- KZIA 06-17-2025
- Dividend Yield
- ACON N/A
- KZIA N/A
- EPS Growth
- ACON N/A
- KZIA N/A
- EPS
- ACON N/A
- KZIA N/A
- Revenue
- ACON $54,601.00
- KZIA $1,655,324.00
- Revenue This Year
- ACON $212.31
- KZIA N/A
- Revenue Next Year
- ACON $92.86
- KZIA N/A
- P/E Ratio
- ACON N/A
- KZIA N/A
- Revenue Growth
- ACON N/A
- KZIA 248000.00
- 52 Week Low
- ACON $6.20
- KZIA $2.86
- 52 Week High
- ACON $3,499.51
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- ACON 36.90
- KZIA 78.10
- Support Level
- ACON $6.29
- KZIA $3.54
- Resistance Level
- ACON $6.80
- KZIA $4.00
- Average True Range (ATR)
- ACON 0.34
- KZIA 0.50
- MACD
- ACON 0.88
- KZIA 0.25
- Stochastic Oscillator
- ACON 65.17
- KZIA 86.07
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.